Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3

BFRI Stock  USD 1.00  0.10  11.11%   
Under 54% of Biofrontera's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Biofrontera suggests that some traders are interested. Biofrontera's investing sentiment shows overall attitude of investors towards Biofrontera.
  
Filed transaction by Biofrontera Officer: Executive Chairman. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Biofrontera insider trading alert for acquisition of restricted stock units by Hermann Luebbert, Officer: Executive Chairman, on 29th of November 2024. This event was filed by Biofrontera with SEC on 2022-05-18. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Biofrontera's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Biofrontera's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Biofrontera Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Biofrontera can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biofrontera Fundamental Analysis

We analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Equity

Return On Equity Comparative Analysis

Biofrontera is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Biofrontera Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biofrontera stock to make a market-neutral strategy. Peer analysis of Biofrontera could also be used in its relative valuation, which is a method of valuing Biofrontera by comparing valuation metrics with similar companies.

Peers

Biofrontera Related Equities

PRFXPainreform   13.67   
0%
71.0%
AKANAkanda Corp   8.57   
0%
44.0%
PROCProcaps Group   7.95   
0%
41.0%
CPHIChina Pharma   0.00   
0%
0%
RGCRegencell Bioscience   0.32   
1.0%
0%
EVOKEvoke Pharma   1.81   
9.0%
0%
SXTCChina SXT   2.50   
13.0%
0%
IXHLIncannex Healthcare   3.37   
17.0%
0%
SHPHShuttle Pharmaceuticals   4.71   
24.0%
0%
PTPIPetros Pharmaceuticals   6.90   
36.0%
0%
CPIXCumberland Pharmaceuticals   7.14   
37.0%
0%
SBFMWSunshine Biopharma   19.05   
100.0%
0%

Complementary Tools for Biofrontera Stock analysis

When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital